Eli Lilly's latest study revealed Zepbound results in an average weight loss of 20.2% compared to 13.7% for Wegovy, with 47% more weight loss overall. The trial, funded by Lilly and involving 751 participants, confirmed previous findings and may influence the obesity drug market. Zepbound's increased sales and approval as a dual GIP and GLP-1 agonist might enhance its competitive edge, but both drugs are associated with mild gastrointestinal side effects. Further data on health outcomes beyond weight loss is anticipated.